Skip to Main Content

Fibrogen presented new clinical trial data on Friday that alleviates concerns about the heart safety of its experimental anemia pill, the drugmaker said.

A pooled safety analysis of approximately 8,000 kidney disease patients enrolled in six Phase 3 clinical trials concluded that the risk of an adverse cardiovascular event — heart attacks, strokes, death, and chest pain — was statistically comparable between the Fibrogen drug called roxadustat and either a placebo or a currently approved anemia injection used as a control.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!